Advanced Prostate Cancer Consensus Conference: APCCC

Patient-Reported Outcomes (PROs): Optimizing Use in Clinical Practice

Details
Alicia K. Morgans presents the rationale, benefits and barriers for Patient-Reported Outcomes (PROs): Optimizing Use in Clinical Practice from the Advanced Prostate Cancer Consensus Conference convened in March 2017. (presentation is 14 minutes) Select References: 1. Patient-Reported Outcomes — Harnessing Patients’ Voices to Improve Clinical Care Ethan Basch, M.D. N Engl J Med 2017; 376:105-108 Ja...

Management of Chronic Pre-existing or Treatment-emergent Adverse Events of the “other" Systemic Therapies - Michael J. Morris

Details
Michael Morris, Memorial Sloan Kettering Cancer Center, New York, US, focuses this discussion on prostate cancer specific aspects of side effects and how we can select the treatments, how to give them in which clinical states, to which patients, at what dose and at what intensity and for what duration. Chemotherapy with docetaxel and cabazitaxel in both mCRPC and mCSPC (non-castrate) is presented...

International Registry To Improve Outcomes in Men With Advanced Prostate Cancer-IRONMAN

Details
Lorelei Mucci presents at the 2017 Advanced Prostate Cancer Consensus Conference in St. Gallen, Switzerland, "International Registry To Improve Outcomes in Men With Advanced Prostate Cancer-IRONMAN". This exclusvie video lecture includes: background, study objectives, overview of design, and what make the IRONMAN registry so unique. View the slides View Interview from the APCCC with Lorelei Mucci...

Circulating tumor cells: Ready for Prime time?

Details
Howard Scher discusses the readiness of liquid biopsy and the process required to make the possibilities of predictive biomarkers a reality. What is needed are assays for predictive biomarkers in circulating tumor cells (CTCs) to inform choice of the treatment at decision points in patient management. He discusses the challenges in demonstrating clinical utility which is the use of the test result...

Lorelei Mucci and Philip Kantoff on Outcomes Research and the IRONMAN Project

Details
Lorelei Mucci and Phil Kantoff discuss the outcomes research of International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerland. Alicia Morgans interviews Lorelei Mucci and Phil Kantoff to discuss the changing treatment landscape for treating prostate cancer and the goal of the IR...

Ian Tannock on the Global view of Advanced Prostate Cancer

Details
Ian Tannock, presented, "Best use of "old and cheap" drugs", at the 2017 Advanced Prostate Cancer Consensus Conference in St. Gallen, Switzerland. Dr. Tannock and Charles Ryan, MD, discuss the greatest challenges faced globally in terms of prostate cancer and the lack of resources. Also, Dr. Tannock shares his views on what clinicians can do to improve the cost of drugs and the importance of educa...

Phil Kantoff on AR-V7: Ready for use in daily clinical decision making

Details
Phil Kantoff presented, "AR-V7- ready for use in daily clinical decision making?" a point/counterpoint discussion at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerland. Neal Shore, MD, interview Dr. Kantoff regarding his Pro position on AR-V7 and the risk benefit of certain drugs and tests and the costs involved. Biographies: Dr. Philip Kantoff is the Chairma...

Susan Halabi on Sub Group Analysis

Details
Susan Halabi presented, "Should we be lumpers or slicers?" as part of the castration-sensitive naive prostate cancer session at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerland. Alicia Morgans, MD interviewed Susan on the utility of the sub group analysis and how clinicians need to think about those in clinical trials. In addition, a discussion around the v...

Welcome Address from Silke Gillessen and Aurelius Omlin at the Advanced Prostate Cancer Consensus Conference

Details
The co-founders of the 2017 Advanced Prostate Cancer Consensus Conference (APCCC), Silke Gillessen and Aurelius Omlin, discuss with Neal Shore different learnings from the 2015 APCCC and how it prepared them for the 2017 meeting. In addition, discussion on the number of countries that are represented and different types of specialists that attended the conference this year. The concept of the modi...

Chris Sweeney on treatment for M1 castration-sensitive/naive disease

Details
Chris Sweeney presented, "Your Patient received ADT plus docetaxel for M1 castration-sensitive/naive disease- now what?", at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerland. Dr. Sweeney describes to Alicia Morgans the balancing act of the amount of treatment and the importance of the right treatment at the right time for the right patient without the bioma...